We focus on developing cost-effective and efficient clinical assets that achieve meaningful value, and our experienced principals are uniquely qualified to achieve this goal.
As leaders within the clinical research organization (CRO) space, our impressive leadership team has submitted more than 70 NDAs throughout their careers, has overseen 250 IND/CTAs/IMPDs and 36 patents, and has participated in more than 2,300 clinical trials across various therapeutic areas—335 as investigators—including over 50 approved products. CinRx’s leadership team also has vast experience with regulatory agencies and documents, including INDs, CTAs and other early phase regulatory documents.
We advance pre-clinical and early clinical stage biopharmaceutical assets to address unmet medical needs, bridging the gap between innovation and validation.
CinRx is a well-funded company that has raised $37 million, and has access to additional funds at subsidiary levels. We are currently targeting initial investments valued between $1M – $5M per asset.